| Acquired Resistance to KRASG12C Inhibition in Cancer MM Awad, S Liu, II Rybkin, KC Arbour, J Dilly, VW Zhu, ML Johnson, ... New England Journal of Medicine 384 (25), 2382-2393, 2021 | 634 | 2021 |
| Mechanisms and clinical activity of an EGFR and HER2 exon 20–selective kinase inhibitor in non–small cell lung cancer JP Robichaux, YY Elamin, Z Tan, BW Carter, S Zhang, S Liu, S Li, T Chen, ... Nature medicine 24 (5), 638-646, 2018 | 455 | 2018 |
| Recruitment of Grb2 and SHIP1 by the ITT-like motif of TIGIT suppresses granule polarization and cytotoxicity of NK cells S Liu, H Zhang, M Li, D Hu, C Li, B Ge, B Jin, Z Fan Cell Death & Differentiation 20 (3), 456-464, 2013 | 324 | 2013 |
| Prostate cancer–associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4 X Dai, W Gan, X Li, S Wang, W Zhang, L Huang, S Liu, Q Zhong, J Guo, ... Nature medicine 23 (9), 1063-1071, 2017 | 291 | 2017 |
| T-cell immunoglobulin and ITIM domain (TIGIT) receptor/poliovirus receptor (PVR) ligand engagement suppresses interferon-γ production of natural killer cells via β-arrestin 2 … M Li, P Xia, Y Du, S Liu, G Huang, J Chen, H Zhang, N Hou, X Cheng, ... Journal of Biological Chemistry 289 (25), 17647-17657, 2014 | 251 | 2014 |
| Synergistic Immunostimulatory Effects and Therapeutic Benefit of Combined Histone Deacetylase and Bromodomain Inhibition in Non-small Cell Lung Cancer WKK Adeegbe D, Liu Y, Lizotte PH, Kamihara Y, Aref AR, Almonte C, Dries R ... Cancer Discov., 2017 | 138 | 2017 |
| Targeting HER2 Aberrations in Non–Small Cell Lung Cancer with Osimertinib S Liu, S Li, J Hai, X Wang, T Chen, MM Quinn, P Gao, Y Zhang, H Ji, ... Clinical Cancer Research 24 (11), 2594-2604, 2018 | 133 | 2018 |
| Mobocertinib (TAK-788): A Targeted Inhibitor of EGFR Exon 20 Insertion Mutants in Non–Small Cell Lung Cancer F Gonzalvez, S Vincent, TE Baker, AE Gould, S Li, SD Wardwell, ... Cancer Discovery 11 (7), 1672-1687, 2021 | 131 | 2021 |
| BET Bromodomain Inhibition Cooperates with PD-1 Blockade to Facilitate Antitumor Response in Kras-Mutant Non–Small Cell Lung Cancer DO Adeegbe, S Liu, MM Hattersley, M Bowden, CW Zhou, S Li, R Vlahos, ... Cancer immunology research 6 (10), 1234-1245, 2018 | 95 | 2018 |
| Assessing Therapeutic Efficacy of MEK Inhibition in a KRASG12C-Driven Mouse Model of Lung Cancer S Li, S Liu, J Deng, EA Akbay, J Hai, C Ambrogio, L Zhang, F Zhou, ... Clinical Cancer Research 24 (19), 4854-4864, 2018 | 65 | 2018 |
| Cleavage of survivin by Granzyme M triggers degradation of the survivin-X-linked inhibitor of apoptosis protein (XIAP) complex to free caspase activity leading to cytolysis of … D Hu, S Liu, L Shi, C Li, L Wu, Z Fan Journal of Biological Chemistry 285 (24), 18326-18335, 2010 | 54 | 2010 |
| Identification of SERPINB1 as a physiological inhibitor of human granzyme H L Wang, Q Li, L Wu, S Liu, Y Zhang, X Yang, P Zhu, H Zhang, K Zhang, ... The Journal of Immunology 190 (3), 1319-1330, 2013 | 50 | 2013 |
| PS341 inhibits hepatocellular and colorectal cancer cells through the FOXO3/CTNNB1 signaling pathway Z Yang, S Liu, M Zhu, H Zhang, J Wang, Q Xu, K Lin, X Zhou, M Tao, C Li, ... Scientific reports 6 (1), 22090, 2016 | 43 | 2016 |
| Synergy of WEE1 and mTOR Inhibition in Mutant KRAS-Driven Lung Cancers J Hai, S Liu, L Bufe, K Do, T Chen, X Wang, C Ng, S Li, MS Tsao, ... Clinical Cancer Research 23 (22), 6993-7005, 2017 | 42 | 2017 |
| Targeting HER2 Exon 20 Insertion–Mutant Lung Adenocarcinoma with a Novel Tyrosine Kinase Inhibitor Mobocertinib H Han, S Li, T Chen, M Fitzgerald, S Liu, C Peng, KH Tang, S Cao, ... Cancer research 81 (20), 5311-5324, 2021 | 40 | 2021 |
| CD54-NOTCH1 axis controls tumor initiation and cancer stem cell functions in human prostate cancer C Li, S Liu, R Yan, N Han, KK Wong, L Li Theranostics 7 (1), 67, 2017 | 40 | 2017 |
| NK cells mediate synergistic antitumor effects of combined inhibition of HDAC6 and BET in a SCLC preclinical model Y Liu, Y Li, S Liu, DO Adeegbe, CL Christensen, MM Quinn, R Dries, ... Cancer research 78 (13), 3709-3717, 2018 | 39 | 2018 |
| Use of Ex Vivo Patient-Derived Tumor Organotypic Spheroids to Identify Combination Therapies for HER2 Mutant Non–Small Cell Lung Cancer E Ivanova, M Kuraguchi, M Xu, AJ Portell, L Taus, I Diala, AS Lalani, ... Clinical Cancer Research 26 (10), 2393-2403, 2020 | 32 | 2020 |
| Structural insights into the substrate specificity of human granzyme H: the functional roles of a novel RKR motif L Wang, K Zhang, L Wu, S Liu, H Zhang, Q Zhou, L Tong, F Sun, Z Fan The Journal of Immunology 188 (2), 765-773, 2012 | 27 | 2012 |
| Adeno-to-squamous transition drives resistance to KRAS inhibition in LKB1 mutant lung cancer X Tong, AS Patel, E Kim, H Li, Y Chen, S Li, S Liu, J Dilly, KS Kapner, ... Cancer Cell 42 (3), 413-428. e7, 2024 | 13 | 2024 |
